Leap Therapeutics
Leap Therapeutics
  • About
    • About
    • Contact Us
  • Pipeline
    • Pipeline
    • DKN-01 Programs
      • Gastric Cancer
      • Colorectal Cancer
      • Endometrial Cancer
      • Prostate Cancer
      • Lung Cancer
    • Anti-CLDN18.2 Programs
      • FL-301 (NBL-015)
      • FL-302 (NBL-016)
    • FL-501
  • Science
    • Science
    • DKK1
    • DKN-01
    • Claudin18.2
    • GDF15
  • Patients
    • Patients
    • Expanded access
  • Careers
  • Investors
    • Investors
    • Stock Information
    • News Releases
    • Presentations & Events
    • Financial Information
    • Corporate Governance
    • Information Request

Leap therapeutics
47 Thorndike Street, Suite B1-1 Cambridge, MA 02141 USA
+1 617 714 0360

Business inquiries
bd@leaptx.com

Investor inquiries
ir@leaptx.com

  • About
  • Contact Us
  • Careers
  • Pipeline
  • DKN-01 Programs
  • Anti-CLDN18.2 Programs
  • FL-501
  • Patients
  • Expanded access
  • Science
  • DKK1
  • DKN-01
  • Claudin18.2
  • GDF15
  • Investors
  • Stock Information
  • News Releases
  • Presentations & Events
  • Financial Information
  • Corporate Governance
  • Information Request
  • © 2023 Leap Therapeutics, Inc.
  • All Rights Reserved.
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
You are now leaving leaptx.com

We are not responsible for the content, views, or privacy policies of this third-party site